New York, USA, June 08, 2023 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Market is Expected to Showcase Significant Growth, Predicts DelveInsight | Key Companies in the Space - Protara, Janssen, Tyra, Pfizer, Roche, CG Oncology, ImmunityBio, Theralase, enGene, SURGE
The non-muscle invasive bladder cancer market is predicted to surge owing to the launch of novel drugs by key companies such as UroGen Pharma, Pfizer, Roche, CG Oncology, ImmunityBio, Theralase, enGene, SURGE Therapeutics, and others, along with improved diagnosis during the forecast period (2023–2032).
DelveInsight’s Non-Muscle Invasive Bladder Cancer Market Insights report includes a comprehensive understanding of current treatment practices, non-muscle invasive bladder cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Non-Muscle Invasive Bladder Cancer Market Report
- As per DelveInsight analysis, the non-muscle invasive bladder cancer market size was ~USD 2 billion in the 7MM in 2022 and it is expected to grow positively owing to several underline factors during the study period (2019–2032).
- According to DelveInsight estimates, the total diagnosed prevalent cases of NMIBC in the US was approximately 200K cases in 2022, which is expected to increase in the study period (2019–2032).
- Leading non-muscle invasive bladder cancer companies such as UroGen Pharma, Pfizer, Roche, CG Oncology, ImmunityBio, Theralase, enGene, SURGE Therapeutics, Aura Biosciences, UroGen Pharma Ltd., FKD Therapies Oy, ImmunityBio, Inc., Protara Therapeutics, Janssen Research & Development, LLC, Tyra Biosciences, Inc, and others are developing novel non-muscle invasive bladder cancer drugs that can be available in the non-muscle invasive bladder cancer market in the coming years.
- Some of the key therapies for non-muscle invasive bladder cancer treatment include UGN-102, Sasanlimab (PF-06801591), TECENTRIQ, CG0070, N-803, TLD-1433, EG-70, STM-416, AU-011, UGN-102, ADSTILADRIN, BCG+N-803, TARA-002, TAR-200, TYRA-300, and others.
- In December 2022, US FDA approved ADSTILADRIN (nadofaragenefiradenovec-vncg), a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-riskBacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
Discover which therapies are expected to grab the major non-muscle invasive bladder cancer market share @ Non-Muscle Invasive Bladder Cancer Market Report
Non-Muscle Invasive Bladder Cancer Overview
Non-muscle invasive bladder cancer (NMIBC) is a type of bladder cancer. NMIBC is a type of cancer that exclusively grows in the thin tissue on the interior surface of the bladder. The bladder muscle is not implicated in NMIBC, and the tumor does not spread outside the bladder. The most common symptom of bladder cancer, which is generally painless, is blood in the urine. Other NMIBC symptoms include frequent and urgent urination, pain when passing pee, pain in the lower abdomen, and back pain. Doctors determine the stage of your bladder cancer by examining how far the tumors have spread into the bladder. This is known as the T stage. There are three T stages of nonmuscle invasive bladder cancer: Tis or CIS, Ta, and T1.
The healthcare professional will first perform a comprehensive medical history and physical exam to diagnose NMIBC, and then the patient will be sent to a urologist who will run additional tests to confirm the diagnosis. Urine cytology, blood tests, CT scans, cystoscopy, and rigid cystoscopy are among the diagnostics used to diagnose NMIBC.
Non-Muscle Invasive Bladder Cancer Epidemiology Segmentation
The non-muscle invasive bladder cancer epidemiology section provides insights into the historical and current non-muscle invasive bladder cancer patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The non-muscle invasive bladder cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Prevalent Cases of Bladder Cancer
- Non-Muscle Invasive Bladder Cancer Diagnosed Prevalent Cases
- Non-Muscle Invasive Bladder Cancer Age-specific Diagnosed Prevalence
- Non-Muscle Invasive Bladder Cancer Tumor Stage-specific Diagnosed Prevalence
- Non-Muscle Invasive Bladder Cancer Grade-specific Diagnosed Prevalence
- Non-Muscle Invasive Bladder Cancer Risk-specific Diagnosed Prevalence
Download the report to understand which factors are driving non-muscle invasive bladder cancer epidemiology trends @ Non-Muscle Invasive Bladder Cancer Epidemiological Insights
Non-Muscle Invasive Bladder Cancer Treatment Market
NMIBC is still a difficult disease to treat, with significant rates of recurrence and progression associated with existing treatments. The high rates of progression and recurrence with current therapy for NMIBC demand lifelong active surveillance, making bladder cancer the most expensive malignancy to treat from diagnosis to death, and increasing the need for novel therapeutics in NMIBC patients. NMIBC is a broad subtype of urothelial bladder cancer with a wide range of recurrence and progression rates. Risk-adapted treatment is critical for balancing treatment-related side effects with effective disease control, and there are numerous nomograms and ways to help, each with particular limits.
The current NMIBC treatment options include KEYTRUDA (pembrolizumab), ADSTILADRIN, surgery, intravesical immunotherapy (BCG), and intravesical chemotherapy. Intermediate- or high-risk NMIBC is often treated with transurethral resection of the bladder tumor (TURBT), followed by adjuvant BCG immunotherapy, which is the gold standard treatment for lowering tumor recurrence rates and avoiding subsequent stage advancement. TURBT with fulguration followed by intravesical therapy within 24 hours is the most common treatment for stage 0 bladder cancer. Sometimes no additional therapy is required. A cystoscopy is then performed every 3-6 months to check for signs of cancer recurrence. If BCG fails, Valrubicin may be administered. However, not all experts agree on this approach.
To know more about non-muscle invasive bladder cancer treatment, visit @ Non-Muscle Invasive Bladder Cancer Treatment Drugs
Key Non-Muscle Invasive Bladder Cancer Therapies and Companies
- UGN-102: UroGen Pharma
- Sasanlimab (PF-06801591): Pfizer
- TECENTRIQ: Roche
- CG0070: CG Oncology
- N-803: ImmunityBio
- TLD-1433: Theralase
- EG-70: enGene
- STM-416: SURGE Therapeutics
- AU-011: Aura Biosciences
- UGN-102: UroGen Pharma Ltd.
- ADSTILADRIN: FKD Therapies Oy
- BCG+N-803: ImmunityBio, Inc.
- TARA-002: Protara Therapeutics
- TAR-200: Janssen Research & Development, LLC
- TYRA-300: Tyra Biosciences, Inc
Learn more about the FDA-approved drugs for non-muscle invasive bladder cancer @ Drugs for Non-Muscle Invasive Bladder Cancer Treatment
Non-Muscle Invasive Bladder Cancer Market Dynamics
The non-muscle invasive bladder cancer market is expected to change in the coming years. Several trials are currently underway that may yield data that will improve oncologist practice and so improve the short-and long-term prognosis for NMIBC. The growing prevalence of NMIBC creates a potential opportunity to raise awareness and innovate therapies to drive the NMIBC market. Moreover, there are few medicines available for the treatment and diagnostics of NMIBC, creating the lucrative potential for developing therapies. In addition, increasing R&D activities to introduce biomarkers for better diagnosis and combination therapy with BCG could propel the growth of the NMIBC market.
Furthermore, the expected introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are likely to boost the growth of the non-muscle invasive bladder cancer market in the 7MM.
However, certain factors may affect the growth of the non-muscle invasive bladder cancer market. Current chemotherapy, immunotherapy, and BCG all have negative side effects. Lack of technical reach, general population knowledge, and inadequate diagnosis in many emerging markets are major constraints to the growth of the NMIBC market. Moreover, many accessible treatments for NMIBC are off-label, and thus frequently favor over-the-counter medication, which can pose a danger to incoming approved drugs due to high cost.
Furthermore, the non-muscle invasive bladder cancer market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the non-muscle invasive bladder cancer market growth.
| Report Metrics | Details |
| Study Period | 2019–2032 |
| Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Non-Muscle Invasive Bladder Cancer Market Size in 2022 | USD 2 Billion |
| Key Non-Muscle Invasive Bladder Cancer Companies | UroGen Pharma, Pfizer, Roche, CG Oncology, ImmunityBio, Theralase, enGene, SURGE Therapeutics, Aura Biosciences, UroGen Pharma Ltd., FKD Therapies Oy, ImmunityBio, Inc., Protara Therapeutics, Janssen Research & Development, LLC, Tyra Biosciences, Inc, and others |
| Key Non-Muscle Invasive Bladder Cancer Therapies | UGN-102, Sasanlimab (PF-06801591), TECENTRIQ, CG0070, N-803, TLD-1433, EG-70, STM-416, AU-011, UGN-102, ADSTILADRIN, BCG+N-803, TARA-002, TAR-200, TYRA-300, and others |
Scope of the Non-Muscle Invasive Bladder Cancer Market Report
- Therapeutic Assessment: Non-Muscle Invasive Bladder Cancer current marketed and emerging therapies
- Non-Muscle Invasive Bladder Cancer Market Dynamics: Attribute Analysis of Emerging Non-Muscle Invasive Bladder Cancer Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Non-Muscle Invasive Bladder Cancer Market Access and Reimbursement
Discover more about non-muscle invasive bladder cancer drugs in development @ Non-Muscle Invasive Bladder Cancer Clinical Trials
Table of Contents
| 1. | Non-Muscle Invasive Bladder Cancer Market Key Insights |
| 2. | Non-Muscle Invasive Bladder Cancer Market Report Introduction |
| 3. | Non-Muscle Invasive Bladder Cancer Market Overview at a Glance |
| 4. | Non-Muscle Invasive Bladder Cancer Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Non-Muscle Invasive Bladder Cancer Treatment and Management |
| 7. | Non-Muscle Invasive Bladder Cancer Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Non-Muscle Invasive Bladder Cancer Marketed Drugs |
| 10. | Non-Muscle Invasive Bladder Cancer Emerging Drugs |
| 11. | Seven Major Non-Muscle Invasive Bladder Cancer Market Analysis |
| 12. | Non-Muscle Invasive Bladder Cancer Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Non-Muscle Invasive Bladder Cancer Epidemiology Forecast
Non-Muscle Invasive Bladder Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted non-muscle invasive bladder cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Non-Muscle Invasive Bladder Cancer Pipeline
Non-Muscle Invasive Bladder Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-muscle invasive bladder cancer companies, including UroGen Pharma, CG Oncolgy, Sasanlimab, Sesen Bio, Theralase Technologies, Asieris Pharmaceuticals, Hamlet Pharma, AstraZeneca, Viralytics, ImmunityBio, Prokarium, among others.
Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bladder cancer companies including RemeGen Co., Ltd., Taiho Oncology, Inc., Xennials Therapeutics, Flame Biosciences, among others.
Muscle-Invasive Bladder Cancer Pipeline
Muscle-Invasive Bladder Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key muscle-invasive bladder cancer companies, including SOTIO a.s., Celon Pharma SA, Shanghai PerHum Therapeutics Co., Ltd., 4D Pharma PLC, among others.
Muscle-Invasive Bladder Cancer Market
Muscle-Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key muscle-invasive bladder cancer companies including SOTIO a.s., Celon Pharma SA, Shanghai PerHum Therapeutics Co., Ltd., 4D Pharma PLC, among others.
Other Trending Reports
Alopecia Market | Invasive Candidiasis Market | Bronchial Spasm Market | Chronic Gout Market | Hpv-Induced Cancers Market | Meningioma Market | Lewy Body Dementia Market | Anti-Gbm Disease Market | Colorectal Cancer CRC Market | Cervical Intraepithelial Neoplasia Market | Carpal Tunnel Syndrome Market | Nonalcoholic Steatohepatitis Market | AIDS Related Kaposis Sarcoma Market | Progressive Supranuclear Palsy Market | Tropical Spastic Paraparesis Market | Secondary Progressive Multiple Sclerosis SPMS Market | Systemic Sclerosis-Associated Interstitial Lung Disease Market | Reactive Airway Disease Market | Ptosis Market | AL Amyloidosis Market | Abdominal Aortic Aneurysm Market | X-Linked Retinitis Pigmentosa Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
